Chinese scientists will perform the world’s first genetic editing trial on humans this month, in an attempt to find a cure for lung cancer. Should the approach prove safe, we will consider expanding our research,” Mr. Lu said. Mr. Lu believed that CRISPR-Cas9 technology has the potential to revolutionise the treatment of blood diseases, tumours and other genetic diseases. “It is like building a cancer-fighting army outside the patient body,” Mr. Lu said. However, the T cells might also attack normal tissue, Mr. Lu said, this first phase of the trial aims to determine whether the approach is safe.

Source: The Hindu August 02, 2016 16:30 UTC